1-苄基-3-丙基脲 | 197727-61-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄基-3-丙基脲
• 英文名称: 1-benzyl-3-propylurea
• CAS: 197727-61-0
• 化学式: C₁₁H₁₆N₂O
• mdl: MFCD02336831
• 分子量: 192.261
• InChiKey: ZDZFEBBLXUPXFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-苄基-3-丙基脲 在 sodium dithionite 、 乙酸酐 、 溶剂黄146 、 sodium nitrite 作用下， 以 乙醇 为溶剂， 反应 3.5h， 生成 5,6-diamino-1-benzyl-3-propyl-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  A₁ Adenosine Receptor Antagonists as Ligands for Positron Emission Tomography (PET) and Single-Photon Emission Tomography (SPET)

  摘要：

  The high affinity of 8-cyclopentyl-1,3-dipropylxanthine (CPX) for the A(1) adenosine receptor (A(1)AR) provides a good lead for developing radioligands suitable for positron emission tomography (PET) and single-photon emission tomography (SPET). This study tested the hypothesis that the kinds of chemical modifications made in the synthesis of CPX analogues containing carbon-ii, fluorine-18, or radioiodine will not alter affinity for the A(1)AR. This report describes the synthesis and radioligand binding assays of unlabeled CPX analogues having methyl, 2-methoxyethyl, 2-fluoropropyl, or 3-fluoropropyl substituents, respectively, at either N-1 (13a-d) or N-3 (8a-d) or an (E)-3-iodoprop-2-en-1-yl substituent at N-3 (8f). Compounds 8d,f and 13b,d antagonized the binding of [H-3]CPX to the A(1)AR of rat brain with affinities similar to those of CPX; compound 8c was twice as potent as CPX. Analogues 8a,b and 13a were less potent than CPX, but for each the K-i of antagonism was greater than or equal to 0.5 nM. Attempts to iodinate the 8-(4-hydroxyphenyl) analogue of CPX failed, probably because the xanthine substituent strongly deactivated the phenol toward electrophilic iodination. In summary, several of the modifications of the propyl groups of CPX needed to produce ligands for imaging by PET and SPET preserve or enhance affinity for the A(1)AR.

  DOI：

  10.1021/jm9705465
• 作为产物：
  描述：

  氧代[(苯基甲基)氨基]乙酸乙酯 在 水 、 lithium hydroxide 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 19.0h， 生成 1-苄基-3-丙基脲
  参考文献：
  名称：

  支持无电解质的草酸阳极氧化为异氰酸酯：一种获得尿素、氨基甲酸酯和硫代氨基甲酸酯的便捷方法

  摘要：

  我们报告了一种新的电化学无负载电解质方法，用于通过草酸氧化合成尿素、氨基甲酸酯和硫代氨基甲酸酯。这种简单、实用且无光气的路线包括在有机碱存在下通过草酸的阳极脱羧原位生成异氰酸酯中间体，然后一锅加入合适的亲核试剂以提供相应的尿素，氨基甲酸酯和硫代氨基甲酸酯。此程序适用于不同的胺、醇和硫醇。此外，当使用单程连续电化学流动条件并且该反应在碳石墨 C gr /C gr 在流动池中，可以在 6 分钟的停留时间内以高产率获得尿素化合物，解锁在批量条件下无法访问的底物，同时易于扩展。

  DOI：

  10.1021/acs.oprd.1c00112

文献信息

• NOVEL REVAMIPIDE PRODRUGS, PREPARATION METHOD AND USE THEREOF
  申请人：SAMJIN PHARMACEUTICAL CO., LTD.

  公开号：US20150141409A1

  公开（公告）日：2015-05-21

  Disclosed are a novel rebamipide prodrug, a method for preparing the same, and use thereof. Also, a pharmaceutical composition comprising the novel rebamipide prodrug as an active ingredient is provided. The rebamipide prodrug is increased 25-fold in absorption rate compared to rebamipide itself, and can be applied to the prophylaxis or therapy of gastric ulcer, acute gastritis, chronic gastritis, xerophthalmia, cancer, osteoarthritis, rheumatoid arthritis, or obesity.

  揭示了一种新型的雷巴米特前药，以及其制备方法和用途。此外，提供了一种含有该新型雷巴米特前药作为活性成分的药物组合物。与雷巴米特本身相比，雷巴米特前药的吸收速率增加了25倍，可用于预防或治疗胃溃疡、急性胃炎、慢性胃炎、干眼症、癌症、骨关节炎、类风湿性关节炎或肥胖症。
• Stabilization of the hindered urea bond through de-<i>tert</i>-butylation
  作者：Yingfeng Yang、Hanze Ying、Yunchao Jia、Yingying Chen、Jianjun Cheng

  DOI：10.1039/d1cc00715g

  日期：——

  A facile acid-assisted de-tert-butylation reaction that can instantly “turn off” the dynamicity of hindered urea bonds (HUBs) and stabilize HUB-containing structures.

  一种简便的酸辅助的脱tert-丁基化反应，可以立即“关闭”受阻尿素键（HUBs）的动态性并稳定含有HUB的结构。
• [EN] INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS INDAZOLE COMME ANTAGONISTES DES RÉCEPTEURS CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009134666A1

  公开（公告）日：2009-11-05

  Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  揭示了吲唑烯化合物，其作为CCR1活性拮抗剂是有用的，因此可用于治疗通过CCR1活性介导或维持的多种疾病和疾病，包括自身免疫疾病，如类风湿性关节炎和多发性硬化症。还披露了包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS
  申请人：Bayer CropScience AG

  公开号：US20150322094A1

  公开（公告）日：2015-11-12

  Use of substituted 2,3-dihydro-1-benzofuran-4-carboxylic acids of the general formula (I) or salts thereof where the radicals in the general formula (I) are as defined in the description, for increasing stress tolerance in plants with respect to abiotic stress, for enhancing plant growth and/or for increasing plant yield, and specific processes for preparing the aforementioned compounds.

  使用通式（I）或其盐代替2,3-二氢-1-苯并呋喃-4-羧酸，其中通式（I）中的基团如描述中定义的，用于增加植物对非生物胁迫的耐受性，促进植物生长和/或增加植物产量，并用于制备上述化合物的特定过程。
• Straightforward carbamoylation of nucleophilic compounds employing organic azides, phosphines, and aqueous trialkylammonium hydrogen carbonate
  作者：Andrey Yagodkin、Kerstin Löschcke、Janne Weisell、Alex Azhayev

  DOI：10.1016/j.tet.2010.01.017

  日期：2010.3

  the intermediate formation of the corresponding isocyanate, which, in turn, reacts further with a nucleophilic reagent also present in the mixture and results in carbamoylation with good yield. On the basis of this reaction a practical carbamoylation procedure was devised and a comparative study on suitability of different solvents and phosphorus (III) derivatives for carbamoylation reaction was conducted

  在碳酸氢三烷基铵水溶液的存在下，施陶丁格反应导致相应异氰酸酯的中间形成，该异氰酸酯又与混合物中也存在的亲核试剂进一步反应，并以高收率进行氨基甲酰化反应。在此反应的基础上，设计了一种实用的氨基甲酰化方法，并进行了对比研究，研究了不同溶剂和磷（III）衍生物对氨基甲酸酯化反应的适用性。该方法的多功能性通过不同类别的亲核化合物（包括氨基甲基树脂和在有机溶剂中显示不良溶解性的天然化合物）的实例得到证明。